每周一次替尔泊肽治疗日本肥胖症患者的疗效与安全性(SURMOUNT-J):一项多中心、随机、双盲、安慰剂对照的3期试验
该多中心随机双盲安慰剂对照3期试验纳入225例日本肥胖症非糖尿病成人,评估每周一次替尔泊肽10 mg或15 mg联合生活方式干预的疗效与安全性。第72周时,替尔泊肽10 mg和15 mg组体重降幅均显著大于安慰剂组,达至少5%体重下降的比例也更高;替尔泊肽组治疗中出现的不良事件更常见,最常见为胃肠道症状,因不良事件停药少见。
要点
- 替尔泊肽10 mg和15 mg组第72周体重较基线降幅均显著大于安慰剂组。
- 第72周替尔泊肽10 mg和15 mg组达至少5%体重下降的比例均显著高于安慰剂组。
- 替尔泊肽组治疗中出现的不良事件更常见,最常见为胃肠道症状,因不良事件停药少见。
核心结论
- 在日本肥胖症成人中,替尔泊肽治疗72周较安慰剂带来有临床意义的体重下降,安全性特征与全球人群中所见一致。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、3期试验,评估替尔泊肽作为生活方式干预辅助的疗效与安全性。
- 纳入日本肥胖症成人(BMI ≥27 kg/m2且伴≥2项肥胖相关健康障碍,或BMI ≥35 kg/m2且伴≥1项肥胖相关健康障碍),排除糖尿病。
- 按1:1:1经计算机生成随机序列分配接受每周一次皮下替尔泊肽10 mg、15 mg或安慰剂。
- 共同主要终点为第72周体重平均百分比变化和达至少5%体重下降的受试者比例,采用疗效估计量。
- 2021年5月10日至2023年6月24日筛查413例,随机分配267例;因排除一个研究中心,改良意向治疗(mITT)人群为225例(男133例[59%],女92例[41%],平均年龄50.8岁[SD 10.7]),替尔泊肽10 mg组73例、15 mg组77例、安慰剂组75例,其中192例(85%)完成研究和治疗。
主要发现
- 第72周体重变化相对安慰剂的估计治疗差异:替尔泊肽10 mg为-16.1%(95% CI -18.7至-13.5;p<0.0001),替尔泊肽15 mg为-21.1%(95% CI -23.6至-18.5;p<0.0001)。
- 第72周达至少5%体重下降的比例:替尔泊肽10 mg组71例中67例(94%)、15 mg组76例中73例(96%),均高于安慰剂组75例中15例(20%)(均p<0.0001)。
- 替尔泊肽还改善了心脏代谢和体成分指标。
- 治疗中出现的不良事件发生率:替尔泊肽10 mg组61例(84%)、15 mg组66例(86%),高于安慰剂组52例(69%),最常见为胃肠道症状。
- 因不良事件停药少见:安慰剂组3例(4%)、替尔泊肽10 mg组1例(1%)、替尔泊肽15 mg组0例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on tirzepatide in Asian patients with obesity are limited. This study aimed to gain a better understanding of tirzepatide for treatment of Japanese patients with obesity disease (BMI ≥25 kg/m2 with excessive fat accumulation) as defined by the Japanese Society for the Study of Obesity. METHODS: This was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of tirzepatide as an adjunct to lifestyle modifications. Japanese adults with obesity disease (BMI ≥27 kg/m2 accompanied by ≥2 obesity-related health disorders or ≥35 kg/m2 accompanied by ≥1 obesity-related health disorders), excluding diabetes, were assigned 1:1:1 via computer-generated random sequence to receive once weekly subcutaneous tirzepatide (10 mg or 15 mg) or placebo. Coprimary endpoints were the mean percent change in bodyweight and the proportion of participants achieving at least 5% bodyweight reduction at week 72, using the efficacy estimand. Efficacy and safety were assessed in the modified intention-to-treat (mITT) population. This study is registered with ClinicalTrials.gov, NCT04844918. FINDINGS: Between May 10, 2021, and June 24, 2023, 413 participants were screened, and 267 were randomly assigned. Due to exclusion of one study site, the mITT population was 225 participants (133 [59%] men and 92 [41%] women, mean age 50·8 [SD 10·7] years), with 73 in the tirzepatide 10 mg group, 77 in the tirzepatide 15 mg group, and 75 in the placebo group, of whom 192 (85%) completed both study and treatment. Estimated treatment differences relative to placebo in change in bodyweight at week 72 were -16·1% (95% CI -18·7 to -13·5; p<0·0001) and -21·1% (95% CI -23·6 to -18·5; p<0·0001) following tirzepatide 10 mg and 15 mg, respectively. At week 72, a higher proportion of participants achieved at least 5% bodyweight reduction with tirzepatide 10 mg (67 [94%] of 71) and 15 mg (73 [96%] of 76) compared with placebo (15 [20%] of 75; both p<0·0001). Cardiometabolic and body composition indices were also improved with tirzepatide. Participants treated with tirzepatide experienced treatment-emergent adverse events more frequently (10 mg: n=61 [84%]; 15 mg: n=66 [86%]) than those who received placebo (52 [69%]), most commonly gastrointestinal symptoms. Study discontinuations due to adverse events were infrequent (placebo: n=3 [4%]; tirzepatide 10 mg: n=1 [1%]; tirzepatide 15 mg: n=0). INTERPRETATION: In Japanese adults with obesity disease, tirzepatide provided clinically a meaningful reduction in bodyweight compared with placebo over 72 weeks, with a safety profile consistent with that observed in global populations. FUNDING: Eli Lilly and Company. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.
引用
- Kadowaki T, Kiyosue A, Shingaki T, et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 40031941. doi:10.1016/S2213-8587(24)00377-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。